Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
Psychedelic Medicine – December 01, 2023
Source: OpenAlex
Summary
The hallucinogen Psilocybin can be safely coadministered with Buprenorphine, a crucial medicine for Opioid use disorder. Pharmacology investigations confirmed zero contraindicating effects, preserving Buprenorphine's effectiveness and Psilocybin's subjective effects. This development holds promise for Psychiatry and Psychology, particularly in Psychedelics and Drug Studies. While initial challenges in participant recruitment required adjustments, the safety profile is a key takeaway for future psychotherapist-guided treatments. This paves the way for further exploration into these chemical synthesis and alkaloids in addressing Opioid addiction, avoiding issues in forensic toxicology.
Abstract
Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall generalizability.clinicaltrials.gov ID: NCT05242029.